Register

Melanoma/Skin Cancer   

Questions discussed in this category

Do you utilize surgical and medical treatments when treating patients with erythroplasia of queyrat, bowenoid papulosis or giant condyloma acuminatum?
1 Answer available
Do you routinely collect debulking specimens for paraffin-embedded or frozen section staining prior to taking a Mohs layer for all skin cancers?
If not, what tumor characteristics prompt you to collect debulking specimens for paraffin or frozen section staining? 
3 Answers available
What are your preferred IHC stain(s) for desmoplastic melanoma?
1 Answer available
In your experience, what has been the most effective form of field therapy for your patients with higher burdens of actinic keratoses?
And what factors push you towards the selection of a specific treatment modality?
2 Answers available
What are your top takeaways in Melanoma from ASCO 2022?
What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice...
1 Answer available
Would you irradiate elective lymph nodes for a T1 Merkel cell carcinoma of the head and neck with a negative sentinel lymph node?
Would a history of immunosuppression impact your decision?
1 Answer available
Would you offer adjuvant radiation therapy for a Merkel cell carcinoma limited to the epidermis with close margins?
1 Answer available
Which patients with cSCC could you omit adjuvant radiation following pathologic complete response following cemiplimab?
1 Answer available
In what scenario would you consider dual IO and TKI therapy in advanced stage melanoma?
1 Answer available
What is the incidence of melanoma arising from vitiliginous patches, and do they develop from different mechanisms than melanomas arising from normal skin?
1 Answer available
Would you offer adjuvant radiation for a sebaceous carcinoma of head and neck after wide local excision?
LVSI positive. No other high-risk features. Would you cover lymphatics?
1 Answer available
How would you manage the axilla in a patient with Merkel cell carcinoma of the left forearm with clinically negative, axillary sentinel node positive disease?
Would you recommend axillary dissection, axillary dissection followed by adjuvant radiation, or axillary radiation alone? Does the number of positive ...
1 Answer available
Do you stop PPI when starting patients on immunotherapy?
1 Answer available
Do you treat the ipsilateral neck and primary site for a resected skin cancer with parotid mets?
If the only indication were the parotid mets (primary site resected with no high risk features) would you treat the parotid and neck (assuming skin ca...
1 Answer available
Would you offer adjuvant radiotherapy to an elderly patient with T4 SCC of the scalp and positive margins 6 months after Mohs surgery?
Would you offer RT if there was bone invasion? If there was poor wound healing causing a 6 months delay, would you still offer RT?
1 Answer available
Do you recommend a deep shave biopsy or punch biopsy for sampling concerning melanocytic lesions?
3 Answers available
Would you include interconnecting skin in the radiation volume for a patient with lateral forehead squamous cell carcinoma who will receive radiation to the surgical bed and preauricular lymph nodes?
2 Answers available
Would you consider lymph node basin radiation in a patient with upper extremity Merkel cell carcinoma with one positive SLN but with no other positive lymph nodes found on axillary dissection?
1 Answer available
How would you approach treatment of an elderly patient with recurrent atypical fibroxanthoma (malignant spindle cell neoplasm) after Mohs surgery?
What is the role for surgery vs RT?
1 Answer available
In what scenario would you add systemic therapy with adjuvant radiation therapy in resected, locally-advanced, cutaneous squamous cell carcinoma?
Reference: TROG 05.01 Trial
1 Answer available
What dose/fractionation would you consider for SBRT of uveal melanomas too large for plaque brachytherapy?
2 Answers available
How would you treat a melanoma of the penile skin in a medically inoperable patient?
If radiation, what dose/fractionation and technique?
2 Answers available
How would you manage eccrine porocarcinoma of the great toe with positive superficial groin and pelvic lymph nodes s/p toe amputation and pelvic lymph node dissection?
Would you offer systemic therapy and/or radiation therapy to groin/pelvis? 
1 Answer available
If a BRAF-mutated melanoma patient developed metastatic disease progression on adjuvant anti-PD-1 monotherapy, do you recommend switching to BRAF/MEK targeted therapy or combination nivolumab/ipilimumab?
2 Answers available
What is the role of radiotherapy in medically inoperable, large and or recurrent aggressive basal cell or squamous cell cancer of the skin in high risk areas?
Should definitive radiotherapy be used as a standard approach? If so, what are the dose and technique considerations in treating these complicated tum...
3 Answers available
Would you ever consider SBRT for de novo cutaneous squamous cell carcinoma?
Is there any data to support it? What dose/fractionation would you consider?
1 Answer available
What radiation regimen do you use to palliate bulky melanoma metastases involving the oral cavity?
In this case, I have a patient with widely metastatic cutaneous melanoma (BRAF wild type, NRAS mutated) who is progressing through pembrolizumab and i...
2 Answers available
When would you add an extra radiation dose to compensate for treatment breaks?
Apart from H&N SCC, are there times where adding an extra dose of radiation due to a tx break is appropriate?  Is there a decent equatio...
2 Answers available
How would you treat a high risk Merkel cell carcinoma of the lower leg after R1 re-resection who failed sentinel mapping?
Would you treat the primary site only, include popliteal nodes, or include popliteal and inguinal nodes?
1 Answer available
What is the role of radiation therapy in a patient with diffuse cutaneous melanoma metastases who cannot tolerate systemic therapy?
1 Answer available
What is your preferred radiation therapy technique for treating resected neurotropic squamous cell carcinoma of the facial skin situated near the infraorbital foramen?
3 Answers available
How would you manage a resectable satellite/in-transit melanoma recurrence that developed during adjuvant immunotherapy?
1 Answer available
How would you treat an immunosuppressed patient with high risk cutaneous SCC of the axilla with node positivity on axillary node dissection?
What radiation doses would you use for the scar and axillary nodal regions? Should supraclavicular and/or IMNs be covered? 
1 Answer available
What immunosuppressive agents would be available to patients with a history of melanoma?
Would you use immunosuppression in patients several years after curative treatment for melanoma?
1 Answer available
In what clinical circumstances would you consider re-irradiation for skin cancer?
Would you choose re-treatment with electrons, photons, or brachytherapy?   What dose and fractionation scheme would you employ?
1 Answer available
Do your radiation treatment margins change for cutaneous basal cell carcinoma in the adjuvant setting compared to cutaneous squamous cell carcinoma?
What margins do you use for each cancer for photons vs electrons?   If your margins differ between cBCC and cSCC, why?      
2 Answers available
How would you manage a localized melanoma of the anal canal with sphincter involvement, but without nodal or distant disease?
1 Answer available
How do you manage SCC metastasis to the parotid with unknown primary?
How would your management change in an elderly patient with no surgery verus superficial parotidectomy or total parotidectomy? 
1 Answer available
How would you manage a nodal recurrence of cutaneous SCC if the patient is unable to receive surgery for 6-8 weeks?
In a patient who would be otherwise fit for surgery +/- adjuvant RT, and the delay is caused by COVID-related OR staffing issues, what would be your a...
1 Answer available
How do you recommend differentiating between localized cutaneous melanoma of the perianal skin versus mucosal melanoma of anal canal?
This question arises from a case of a patient with multifocal nodular melanoma with circumferential involvement of the perianal region.
1 Answer available
How do you approach selection of dose and fractionation for definitive treatment of localized skin cancers?
With so many choices listed in NCCN guidelines ranging from 2-7 weeks, what considerations factor into your decision making? 
2 Answers available
How do you approach breast conserving therapy in a woman who has formed bothersome keloids after prior surgeries?
Is there any alteration in approach from the medical, surgical, or radiation oncology perspective that can mitigate the risk of forming keloids withou...
3 Answers available
When would you offer post-op radiation for the treatment of sebaceous carcinoma of the eyelid?
2 Answers available
What is your preferred first-line treatment for metastatic melanoma in a patient with a class 2/non-V600 BRAF mutation?
4 Answers available
What is your preferred adjuvant treatment option for a patient with stage III BRAF-mutated melanoma and a history of a solid organ transplantation on immunosuppressants?
0 Answers available
What surveillance plan would you recommend for stage IV melanoma patients who achieve a CR or stable PR response with immunotherapy?
1 Answer available
What dose would you use for re-irradiation of metastatic melanoma to an inguinal node?
If the inguinal node was previously treated with SBRT 30Gy/5fx and immunotherapy >6 months, what treatment would you recommend?
2 Answers available
Would you offer adjuvant immunotherapy for a melanoma patient with lymphocytic colitis?
1 Answer available
How would you approach an early inguinal recurrence after surgical resection of Merkel Cell carcinoma in the popliteal region?
2 Answers available
What surveillance imaging do you obtain for stage III melanoma patients after completing systemic adjuvant therapy?
1 Answer available
How would you approach radiation treatment of recurrent, BRAF-negative melanoma with left distal leg metastases and two isolated PET-avid inguinal nodes?
The index lesion was located inferior to the left knee and excised appropriately, with an additional in-transit metastasis in the left mid leg. The pa...
1 Answer available
How would you manage a patient with cutaneous SCC of the lower extremity with isolated inguinal nodal involvement?
What is the role and sequence of surgery and/or RT? Which nodal levels would you include in your RT field(s)?
1 Answer available
What is the preferred dose and fractionation regimen for cutaneous squamous cell carcinoma of the thumb?
How would your treatment change for definitive vs post-surgical RT? Does approach differ depending on the anatomic (distal vs proximal and dorsal vs ...
2 Answers available
How do you approach treatment for a patient with uveal melanoma who is not a candidate for plaque brachytherapy
What are the surgical and radiation options? What dose and fractionation scheme is appropriate for fractionated SRS?
2 Answers available
Are there circumstances where you would recommend every 6 week dosing schedule for pembrolizumab monotherapy?
I am considering every 6 week pembrolizumab dosing in patients >70 years old in whom I want to reduce clinic visits for, especially in the context ...
3 Answers available
Would you pursue adjuvant immunotherapy for a resected stage IIIC or IIID, BRAF wild type, melanoma patient with pre-existing ulcerative colitis that is well managed on maintenance infliximab?
1 Answer available
How would you manage recurrent popliteal and inguinal LNs from melanoma?
In a patient with a history of a RLE melanoma s/p WLE and right ILND, how would you treat nodal recurrence? What are the surgical vs non-surgical opt...
1 Answer available
Would you change systemic therapy for metastatic melanoma on BRAF/MEK targeted therapy with excellent extracranial response, but with CNS-only progression?
1 Answer available
What is your preferred adjuvant systemic treatment for resected stage IV melanoma with a BRAF mutation?
Based on available results from the IMMUNED trial, which evaluated the role of adjuvant nivolumab/ipilimumab or nivolumab monotherapy vs placebo in re...
2 Answers available
How would you treat a patient with an keratoacanthoma of the right nasal ala?
What approaches (surgical vs non-surgical) offer the best cosmesis for keratoacanthoma (low grade squamous cell carcinoma) ? 
1 Answer available
What type of surveillance would you recommend following resection of primary mucinous carcinoma of the skin?
1 Answer available
How would you approach treatment of a patient with asymptomatic, oligometastatic basal cell carcinoma?
Is there a role for radiation? Does your approach differ depending on site(s) of  disease, and/or if the patient has Basal-Cell Nevus (Gorlin) sy...
1 Answer available
How do you advise patients on the risk for permanent alopecia following RT to the scalp?
In treating skin cancers of the scalp,  are there any specific constraints you give to the skin itself to prevent alopecia?  How does changi...
2 Answers available
How would you approach the treatment of a patient with a history of cutaneous melanoma and only overt site of disease being a bulky level III axillary lymph node?
Specifically, this patient was unable to tolerate immunotherapy due to severe side effects.
3 Answers available
Would you offer definitive radiation therapy for a Merkel cell carcinoma in which surgical resection would be disfiguring or result in significant dysfunction?
In general, how would you approach such a case with regards to creation of your treatment volumes and dose-fractionation? 
1 Answer available
For Merkel cell carcinoma of the lower extremity with early isolated recurrence in the ipsilateral inguinal nodes, would you include pelvic lymph nodes in the post-operative field following inguinal lymph node dissection?
1 Answer available
Would you continue cemiplimab or pembrolizumab following resection of initially unresectable cutaneous squamous cell carcinoma?
What if pathology showed NED?
3 Answers available
How would you approach a BRAF negative metastatic melanoma patient on immune checkpoint inhibitor therapy with enlarging, symptomatic brain lesions that had previously been treated with SRS?
If on pembrolizumab or nivolumab, when would you escalate to ipilimumab/nivolumab?
1 Answer available
How do you manage MEK inhibitor induced ocular adverse events?
1 Answer available
What is your preferred radiotherapy regimen for palliative treatment of cutaneous T cell lymphoma?
1 Answer available
How would you manage a small recurrent melanoma of the lower eyelid in a patient deemed inoperable?
Would you recommend radiation therapy or immunotherapy? If proceeding with radiation therapy, what dose-fractionation and technique would you utilize?
2 Answers available
Would you recommend post-op RT for an ulcerated Clark's level IV melanoma of the zygomatic/preauricular region following a WLE with diffuse melanoma in-situ at the margins?
What dose-fractionation schedule would you utilize?
1 Answer available
What is the appropriate radiation dose/volume for perianal basal cell carcinoma?
Should concurrent chemotherapy be given? How would you modify the regimen in elderly/frail patients?
1 Answer available
When, if ever, would you consider using encorafenib/binimetinib or vemurafenib/cobimetinib instead of dabrafenib/trametinib for adjuvant treatment of BRAF mutated melanoma?
0 Answers available
Would you treat a locally advanced head and neck cutaneous squamous cell carcinoma with axillary-only mets definitively?
Would you treat with radiation (+/- surgery upfront, if resectable) or systemic therapy?
1 Answer available
Is there benefit in switching between sonedegib to vismodegib or vice versa for patients with unresectable basal cell carcinoma of the face that progresses on first line hedgehog inhibitor?
1 Answer available
What is your approach to adjuvant radiation for anorectal mucosal melanoma s/p wide local excision?
What dose, fractionation and what elective coverage do you recommend?
1 Answer available
What is your approach to elective radiation of the neck with primary cutaneous squamous cell carcinoma?
When do you electively treat the ipsilateral versus ipsi- and contralateral neck?
1 Answer available
Would you start neoadjuvant treatment with immunotherapy or BRAF/MEK inhibitors in a patient with a large regional inoperable BRAF V600E positive melanoma (IIIC)?
1 Answer available
Is there a role for adjuvant therapy, either radiation (+/- chemo), or systemic therapies (immunotherapy, targeted agents or chemotherapy) after resection of anorectal mucosal melanoma?
1 Answer available
How would you approach the treatment of a low grade adnexal carcinoma of the scalp in a patient with prior history of WBRT as a child?
This particular case involves a patient with a frontal scalp low grade eccrine carcinoma status-post excision with positive margin complicated by...
1 Answer available
Would you avoid the use of a TNF inhibitors in patients with a remote history of melanoma, including those with ocular melanoma?
1 Answer available
What dose-fractionation and technique do you use when treating lentigo maligna?
3 Answers available
How would you approach the post-operative radiation treatment volumes for a Merkel cell carcinoma of the hand?
Would you treat the primary site alone, include the hand and arm lymphatics to the epitrochlear nodes (one continious treatment volume from hand to el...
1 Answer available
What is your preferred setup/immobilization for patients with cutaneous malignancy of the toe involving the medial aspect of the digit?
1 Answer available
What dose and fractionation would you use for definitive intent radiation therapy for a metastatic melanoma of the maxillary sinus?
1 Answer available
How would you approach treatment of residual melanoma in situ of the perianal skin?
Would you recommend adjuvant radiotherapy for a patient with positive margins for in situ disease with negative margins for invasive disease? If so, w...
1 Answer available
Is postoperative radiotherapy indicated for a primary parotid gland melanoma?
Would there be any indication for postoperative RT if cervical lymph nodes are negative?
1 Answer available
How do you decide between initial radiotherapy vs systemic therapy in patients with metastatic melanoma and brain metastases?
If neurologic symptoms are absent or controlled, does that affect your treatment decision?
2 Answers available
How would you treat a bulky axillary squamous cell carcinoma of unknown primary in an elderly person?
Assuming no other sites of disease on staging scans, surgery is not an option, and the patient is otherwise healthy with reasonable life expectancy. W...
3 Answers available
Would you consider post-operative radiation therapy for resected malignant melanoma with in-transit metastasis?
In this example, the patient had a resected melanoma with negative margins and the specimen was noted to have two nests of tumor cells in the deep der...
1 Answer available
Would you consider starting immunotherapy concurrently with whole brain radiation for newly diagnosed metastatic (BRAF negative) melanoma with multifocal symptomatic brain metastases?
If so, would you consider it with monotherapy only or also with combined checkpoint blockade?
2 Answers available
Would you offer adjuvant RT for a small merkel cell carcinoma of the lateral canthus with a close margin?
Given the location but no other high risk features would you offer RT?  If so, what dose and fields? 
2 Answers available
Do you ever recommend concurrent chemotherapy for high risk squamous cell skin cancer radiation?
What dose of radiation, what type of chemo, and what indications?
2 Answers available
What are the alternatives to gonioscopy gel to protect the cornea when using internal eye shielding?
In patients with cancers involving the lid requiring superficial x-ray treatment, I use an internal eye shield placed under the lid to protect the cor...
1 Answer available
What dose-fractionation would you utilize for an unresectable localized cutaneous melanoma that has progressed on immunotherapy?
Specifically, for a melanoma of the axilla with proximity to the brachial plexus, how would you approach such a case to minimize chance of radiation-i...
1 Answer available
What dose-fractionation would you recommend for post-operative radiation therapy for an excised cutaneous squamous cell carcinoma of the foot with a skin graft?
Is there an appropriate hypofractionated regimen for such a clinical scenario?
3 Answers available
What is the most appropriate dose-fractionation for an early stage, progressive cutaneous squamous cell carcinoma of the nose in an elderly/frail patient in the setting of the COVID-19 pandemic?
How do counsel patients regarding potential for cartilage necrosis?
5 Answers available
When do you change treatment for an asymptomatic metastatic melanoma with a mixed response after at least 3 months of treatment with a PD-L1 inhibitor?
1 Answer available
Is there any contraindication to concurrent administration of radioactive iodine in a patient on immunotherapy?
A patient with stage 3 melanoma on adjuvant nivolumab needs radioactive iodine for papillary thyroid cancer.
1 Answer available
If small cell carcinoma was found in an axillary lymph node with an unknown primary, would you recommend axillary lymph node dissection prior to chemoradiation?
What would your dosing recommendation be?
2 Answers available
Would you recommend adjuvant radiation for an atypical fibroxanthoma of the scalp that is completed resected with +PNI and +LVI?
What pathologic features are most important when evaluating the possible need for adjuvant therapy?
1 Answer available
Would you offer concurrent chemoradiotherapy and/or adjuvant systemic therapy (chemo or immunotherapy) or for a completely resected stage III Merkel cell after WLE and ALND?
Patient is a  67yo with a pT1 (2.5mm) pN1a merkel cell of the chest, 1 mm deep, widely clear margins, SLN with 1.5mm met, 11 additional axillary ...
2 Answers available
How do you measure the skin dose when you are concerned about dosing to the skin?
Is it possible to get a good measurement with TLDs? TLDs can overestimate the surface dose by 10 - 40%. Do you use a skin diode measurement on the fir...
1 Answer available
For a patient with limited/resectable metastatic melanoma and no evidence of disease after resection, when would you consider doublet immunotherapy rather than nivolumab or pembrolizumab monotherapy?
For instance, in a patient with isolated distant nodal involvement who had the lymph node resected but did not have a lymph node dissection?
1 Answer available
What is your preferred dose-fractionation regimen when treating high-risk SCC of the skin in elderly and/or frail patients?
3 Answers available
How do you manage local recurrence of a resected stage III BRAF WT melanoma occurring during or shortly after completion of adjuvant nivolumab?
Would you offer nodal dissection and/or additional adjuvant immunotherapy in addition to wide local excision?
1 Answer available
How would you manage a high risk SCC of the scalp that has wound healing issues after Mohs surgery?
Would you offer RT? If so, shat dose fractionation do you recommend? 
2 Answers available
When should proton beam therapy be considered for uveal melanoma?
Are there exclusion criteria?
3 Answers available
Is there a maximum time delay in offering adjuvant radiation to patients with wound healing issues for sarcoma and skin cancer patients with aggressive histology and positive margins?
Sometimes wound healing can delay adjuvant radiotherapy by several months. For aggressive histology, such as high grade sarcomas or skin cancers with&...
1 Answer available
Would you offer adjuvant radiation to the surgical bed for a Merkel cell carcinoma of the upper extremity with low-risk features as per the NCCN Guidelines?
*Negative margins, <1cm in size, no LVI, negative SLNB, not immunocompromised, no prior surgery (as well as a negative PET/CT scan).
2 Answers available
What radiation dose, fractionation and volume would you use in an elderly patient with localized extensive anorectal malignant melanoma status post laparoscopic APR?
Would your recommendation change with the following aggressive features: 8 cm, pericolic extension, positive radial margin, perineural invasion presen...
1 Answer available
How do you decide whether or not to give immunotherapy in patients with a history of an isolated, severe autoimmune event?
For instance, not chronic autoimmune diseases (eg RA, IBD) that may relapse/remit but events like Guillan Barre syndrome that is not likely to recur b...
1 Answer available
What dose-fractionation would you use for a recurrent basal cell carcinoma of the right ear concha close to the tympanic membrane status-post multiple Mohs surgeries with close/positive margins?
Further resection is not recommended, as the surgeon is worried about damaging hearing with additional surgery.
2 Answers available
How do you account for tumor growth from pre-operative to intra-operative ultrasound for uveal melanoma?
Do you prescribe to 5mm/apex or use a margin? Do you add time for tumor growth or allow less than the prescription dose to the apex?
2 Answers available
What therapy would you offer a young BRAF wild type patient with metastatic melanoma, who progressed on single agent pembrolizumab?
1 Answer available
How do your adjuvant treatment recommendations change, if at all, for clinically node positive Stage III desmoplastic melanoma?
1 Answer available
Are there guidlines for elective coverage of nodal basins in head and neck for skin cancer removed in the area?
4 Answers available
What dose-fractionation do you use for recurrent SCC (face) that was previously multiply resected and radiated, but has a persistently positive margin after re-resection?
Especially in the setting of prior “standard” adjuvant dose and refusal of the patient to undergo more extensive surgery. Do you recommend...
1 Answer available
For clinically node negative large squamous cell carcinomas of the scalp vertex, would you electively treat the nodes?
If so, which levels? Bilateral? What about parotids or submandibular gland?
1 Answer available
How do you prevent non-healing ulcer when treating patients with cutaneous SCC of the distal lower extremity who have peripheral vascular disease?
These patients are often not surgical candidates, but radiation complications may also be underappreciated.  Do you refer to vascular surgery pri...
2 Answers available
When is postoperative radiation indicated after enucleation of an ocular melanoma?
Is extrascleral extension or optic nerve invasion an indication?  I can find little in the literature or textbooks discussing this issue, likely ...
1 Answer available
How would you treat a patient with BRAF mutated Metastatic Melanoma who has progressed on targeted therapy (Encorafenib + Binimetinib) and Immuotherapy (Nivolumab/Ipilimumab), but yet maintain an excellent performance status?
2 Answers available
Can you use immunotherapy in patients with liver transplants?
With increasing utility of immunotherapy across cancer types, patients with history of solid organ transplants may face need for cancer IO. How do you...
1 Answer available
What are your dose constraints for treating axillary nodal basin in melanoma with 30Gy/5fx?
What are your dose constraints for treating axillary nodal basin in melanoma with the Ballo protocol 30Gy/5fx?
1 Answer available
When do you consider employing the 4-week dosing schedule for nivolumab?
The FDA has approved the new dosing schedule of Nivolumab 480 mg every 4 weeks for multiple disease sites (melanoma, RCC, urothelial carcinoma, SCC of...
5 Answers available
Is there a role for treating actinic keratosis with superficial radiation therapy to widespread areas on scalp?
If so, what is your suggested dose/fractionation? 
1 Answer available
Is there a role for radiation in the treatment of bulky axillary adenopathy in patients with newly diagnosed oligometastatic melanoma?
Should these patients have surgery if resectable? Should RT (SBRT) be directed at metastases during/concurrently with immunotherapy down the road?&nbs...
1 Answer available
Would you recommend surgery +/- adjuvant XRT or definitive XRT in elderly patients with recurrent squamous cell carcinoma of the ear with direct invasion through the cartilage of the helix?
1 Answer available
What is the role of adjuvant radiation therapy for isolated melanoma lymph node metastases, status post resection and found to have extranodal extension?
1 Answer available
What would be your recommended adjuvant treatment approach for a completely excised lymphoepithelial carcinoma of the right nose recurrent in a left level IB lymph node, status-post excisional biopsy?
Would you recommend additional surgery for the violated neck? Or, would you proceed with adjuvant radiation therapy? If so, would you treat ipsilatera...
1 Answer available
What are your recommendation for vaccines in patients while on immunotherapy?
Do you recommend or withhold influenza and pneumonia vaccines while on treatment with checkpoint inhibitors?
1 Answer available
How often are you recommending adjuvant pembrolizumab for resected stage IIB/C melanoma patients?
Based on the KEYNOTE-716 study and Dec 2021 FDA approval
2 Answers available
Would you give adjuvant nivolumab for IIIA melanoma?
Patients with T3aN1a( stage IIIA per AJCC7) were excluded from nivolumab adjuvant trial. Would you consider nivolumab in these patients?
1 Answer available
How would you approach adjuvant radiation therapy for a Merkel cell carcinoma of the cheek in an immunocompromised patient?
For example, in a patient status-post WLE with a close (2.5 mm) deep margin and negative neck node sampling, would clinical (but not pathologic) ...
1 Answer available
How would you treat an SCC of the helix of the ear with posterior auricular nerve involvement s/p surgical resection?
If there are no pre-op photos, what would your fields look like and dose/fractionation?
1 Answer available
How would you approach a patient who progressed on immunotherapy for merkel cell carcinoma?
Checkpoint inhibitors have demonstrated durable responses in clinical trials, which was never seen with cytotoxic chemotherapy in the past. What are t...
1 Answer available
What is your approach to metastatic choroidal melanoma with systemic metastases outside of a clinical trial?
NCCN guidelines recommend both single agent Pembro and/or Ipi/Nivo as first line options. How would you choose between the two? In case of the latter,...
1 Answer available
What is the role of Braftovi (encorafenib) and Mektovi (binimetinib) in combination for unresectable or metastatic melanoma?
The FDA recently approved Braftovi (encorafenib) and Mektovi (binimetinib) in combination for unresectable or metastatic melanoma. When would they be ...
1 Answer available
How would you treat a patient with aggressive metastatic cutaneous squamous cell carcinoma, which is not amenable to surgery or radiation?
2 Answers available
When would you consider neoadjuvant immunotherapy for advanced melanoma?
For example, would you consider this in a patient that would otherwise be eligible for adjuvant treatment (stage III or stage IV with oligometastatic ...
1 Answer available
What dose and fractionation would you recommend for treating the primary site of a patient with metastatic anal melanoma?
1 Answer available
What do you consider to be the regional nodal bed for a Merkel cell carcinoma of the thigh with a positive sentinel node in the inguinal chain?
Would you also radiate the ipsalateral external and/or common iliac nodes?
2 Answers available
In what situations would you treat elective regional lymph nodes for a squamous cell carcinoma of the skin on the extremity/trunk that was clinically node negative?
For example, for a squamous cell carcinoma of the forearm treated with Mohs surgery with negative margins, are there features that would lead you to e...
1 Answer available
When is adjuvant radiotherapy recommended for a high risk squamous cell carcinoma of the skin (non-H&N) if the tumor is resected with widely negative margins and there is no perineural invasion?
Per NCCN, only +/close margins and +PNI are given as indications for adjuvant RT. However, are the presence of other risks factors considered to guide...
1 Answer available
Would you hold immunotherapy if a patient with metastatic melanoma has stable disease for 6 months?
If so, after what duration?
1 Answer available
Would you consider stopping nivo/ipi combination after a CR in a patient with metastatic melanoma?
Can you extrapolate the data on Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma to patients on a...
1 Answer available
How long after achieving a CR would you consider stopping pembrolizumab in metastatic melanoma?
1 Answer available
Is there a role for radiation therapy if squamous cell carcinoma (SCC) is incidentally found in an excised epidermoid cyst?
If the cyst was encapsulated and completely removed and SCC was found incidentally on final pathology, what are some factors that would influence your...
1 Answer available
What is the your choice of treatment after progression or AE following pembrolizumab in metastatic melanoma?
Patient does not have BRAF mutation.
1 Answer available
Is there a difference in the durability of CR based on the dosage of pembrolizumab used in metastatic melanoma?
In this study, doses of 2mg/kg Q3wks, 10mg/kg Q3wks and 10mg/kg Q2wks were used. What did the majority of these patients in CR receive? 
1 Answer available
What are the indications for adjuvant radiotherapy for basal cell carcinoma of the skin of the head and neck?
NCCN lists only substantial perineural invasion.  What about other high-risk adverse features such as histologic subtype, multiple recurrences, d...
1 Answer available
What dose fractionation would you recommend for large (>5 cm) perianal Bowen's disease (squamous cell CIS)?
1 Answer available
What is your approach to the initial treatment of metastatic melanoma patients with NRAS mutations?
How do you treat these patients if they progress after immune checkpoint inhibitors?
1 Answer available
What postop volume would you treat for for cutaneous squamous cell carcinoma of the upper neck with perineural invasion of multiple nerves?
Should nodes always be covered for perineural invasion when that is the only risk factor?
1 Answer available
What dose-fractionation would you use to treat a single large melanoma lung metastasis?
 How does your fractionation choice change if the lesion is abutting the pleura?
1 Answer available
What systemic therapy, if any, would you recommend for a patient with oligometastatic melanoma who is rendered NED after resection?
Would your recommendation change at all depending on time to relapse or original stage of melanoma?
1 Answer available
What would you recommend as adjuvant treatment for a patient with Stage III melanoma?
If staged so due to satellite lesion and negative nodes? How do you decide between adjuvant PD-1 inhibitor or BRAF/MEK inhibition in BRAF-mutated pati...
1 Answer available
What treatment would you offer to a patient after resection of a solitary metastatic melanoma from the brain without evidence of other sites of disease?
Assuming SRS to the resection cavity is advised, would you recommend early immunotherapy to improve outcomes/enhance a possible abscopal eff...
1 Answer available
What dose-fractionation would you recommend for a small basal cell carcinoma of the nasal ala in a patient with poor performance status or transportation difficulties?
5 Answers available
Is there a role for PD-1 inhibitors for metastatic or locally recurrent cutaneous squamous cell carcinomas after failure of first line therapy, EGFR inhibitors?
Is it commonly used if no clinical trials are available?
1 Answer available
Would you treat a patient with HIV or hepatitis C with an anti-PD-1 agent?
These patients have been largely excluded from these trials.  What if the infection is well controlled?
3 Answers available
What risk factors prompt you to treat an early-stage nasal squamous cell carcinoma of the skin with post-operative radiation to the primary and/or elective nodal radiation?
When elective nodal radiation is recommended, which nodes would you treat (i.e. facial, pre-auricular, peri-parotid, levels I-III, etc.)?
1 Answer available
Is it necessary to hold immunotherapy during a 4-6wk steroid taper after resolution of immunotherapy related toxicity?
Would you ever considering re-starting immunotherapy before completing the taper? According to the new guildelines on managing immunotherapy related ...
1 Answer available
How do you approach treatment for metastatic cutaneous squamous cell carcinoma after standard chemotherapy failure?
Is the use of immunotherapy being considered, and if so, is the data extrapolated from treatment of mNSCLC and head and neck SCC?
1 Answer available
Would you offer adjuvant radiation for a <1 cm preauricular sebaceous carcinoma after wide local excision?
Patient underwent a shave biopsy of a 6x5x2mm preauricular lesion that showed moderatley differentiated sebaceous carcinoma with deep and lateral marg...
1 Answer available
Would you recommend adjuvant radiation therapy to the locoregional lymph node basins for Merkel cell carcinoma (MCC) with a solitary macroscopically positive lymph node (LN) without ECE after lymph node dissection?
Per the NCCN guidelines, in this specific scenario, adjuvant radiation therapy to the locoregional lymph nodes after lymph node dissection is not indi...
2 Answers available
How do you manage the elective lymphatics in high risk squamous cell carcinoma of the skin?
In a clinical N0 patient with high risk (large, deeply invasive, poorly differentiated, +PNI, etc) cutaneous SCC of the head and neck, who do you...
2 Answers available
How do you decide whether or not to cover elective lymphatics when treating cutaneous squamous cell carcinoma of the head and neck with definitive RT?
Unlike in post-operative cases, you lack detailed pathologic information in this scenario. Do you base your decision on location, size, and/or patholo...
2 Answers available
How would you manage treatment of keloid that is so large it requests a graft?
What dose/fractionation would yield the lowest risk of graft failure? Does your treatment management change based of location, ex the ear vs back?
1 Answer available
Do you recommend elective lymph node irradiation for a basal cell carcinoma of the skin that is deeply invading muscle?
For example, would you recommend treatment of the cervical and posterior occipital lymphatics for a 4 cm lesion deeply invading the posterior ridge of...
1 Answer available
How do you approach the managment of basal cell carcinoma with only lymph node involvement?
No skin lesion was apparent on exam and extracapsular extension was seen on the excised lymph node. Is radiation therapy sufficient and is there a rol...
3 Answers available
Do you consider alternate therapy with a different anti-PD1 agent after a patient responds to an anti-CTLA4 +/- anti-PD1 agent but develops serious side effects?
Is there data for switching from nivolumab/ipilimumab to pembrolizumab if a patient develops significant pneumonitis but also had a significant radiog...
1 Answer available
What is your preferred approach for the management of choroidal oligometastases?
How do you decide between plaque brachytherapy and external beam approaches? What dose do you use for plaque brachytherapy? For external beam, what do...
1 Answer available
How would you utilize adjuvant radiation therapy in a patient with a cutaneous spindle cell neoplasm of the scalp metastatic to the parotid gland?
What dose-fractionation schedule and treatment volumes would you utilize for adjuvant radiation therapy status-post total parotidectomy with negative ...
1 Answer available
What is your next step in management for a patient with immunotherapy induced pneumonitis that does not improve on high dose steroids for 48 hours?
How do you decide between starting infliximab, MMF, or IVIG? If a patient presents in respiratory failure (nearing or requiring intubation), woul...
1 Answer available
When would you recommend adjuvant radiation therapy for a patient with a completely resected (negative margins) dermatofibrosarcoma protuberans?
1 Answer available
Does anaphylactoid reaction to one immunotherapy agent exclude the possibility of using other immunotherapy agents?
1 Answer available
Do you resume immunotherapy (such as nivolumab) for metastatic melanoma after therapy-induced grade 4 hyperglycemia that has resolved?
Can immune check point inhibitor be restarted if grade 4 hyperglycemia (with acidosis and insulin drip requirement) has resolved?
1 Answer available
How do you manage the neck in patients with cutaneous SCC who are at high risk of nodal disease but had a negative neck dissection?
Is there a minimum amount of nodes you would like to be removed before you omit radiation to the neck? Do you consider other factors when deciding whe...
1 Answer available
Is there an effective treatment for multiple appearances of cutaneous Kaposi's lesions besides radiation?
In a patient who already received 13 courses of radiation (with complete response), is there any other effective treatment?
1 Answer available
Would you start immunotherapy in a patient with metastatic melanoma who is on steroids (e.g. dexamethasone for cerebral edema)?
Or would you try to wait and get the steroids off first?
1 Answer available
Should lymph nodes be treated with postop RT of undifferentiated pleomorphic sarcoma of the head and neck?
Specifically, the cheek? If so, which nodes should be treated and to what dose?    
1 Answer available
How do you approach the management of surgically resected conjunctival melanoma that has recurred locally?
What, if any, is the role of immunotherapy in this situation ?
1 Answer available
In which patients do you offer adjuvant radiation for porocarcinoma?
If a patient has undergone wide local excision with residual disease, but negative margins, is it safe to observe? If adjuvant treatment is indicated,...
1 Answer available
How do you choose between single agent versus combination checkpoint inhibitors for BRAF Wildtype metastatic melanoma?
1 Answer available
How do you manage anticoagulation for patients with DVT/PE who have brain metastases?
Some medical oncologists tend to hold anticoagulation in patients who develop brain metastases for fear of causing intracranial hemorrhage.  Is t...
3 Answers available
How do you treat multi-focal/diffuse non-melanomatous skin cancers of the face and scalp for which you would also want to cover high-risk elective nodes?
Would you treat large/total scalp fields to definitive skin cancer doses? If the patient has a more limited KPS, would you treat sequentially in order...
2 Answers available
Would you ever consider stopping immunotherapy in a patient with metastatic melanoma after achieving a good response?
Would your recommendations change if it was a partial vs complete radiographic response?
1 Answer available
What is your approach to adjuvant treatment to the tumor bed and/or regional lymph nodes for an early stage Merkel cell carcinoma status-post WLE and sentinel lymph node biopsy?
If there is an operationally failed sentinel lymph node biopsy, do you always include RT to regional nodes?
3 Answers available
Do you have a tolerance dose for a skin graft when treating a high-risk skin cancer?
How long would you typically wait between date of surgery and initiation of radiation therapy? What factors influence this decision?
1 Answer available
How do you manage immune-related toxicity from checkpoint inhibitors that is refractory to initial steroid therapy?
What immunosuppressive agents are used and in what order?  Does your approach differ depending on the organ involved, e.g. colitis vs. pneumoniti...
1 Answer available
For newly diagnosed BRAF mutated melanoma with brain metastases, do you prefer to start with targeted therapy or with immunotherapy?
1 Answer available
Do you offer radiation in the setting of a resected desmoplastic melanoma with negative margins given that several retrospective studies show a local control benefit?
If so, how large of a margin would you place on the primary lesion and would you incorporate any adjacent lymph node levels?
3 Answers available
Would you use immune checkpoint inhibitors in patients with well-compensated liver cirrhosis?
Does the risk of severe inflammation of the liver lead you to choose other therapies in in this population?  What about in patients with mild liv...
1 Answer available
How do you manage patients with BRAF V600E-mutated metastatic melanoma who have a mixed radiographic response after several months of therapy with dabrafenib/trametinib?
Does the site of progression or response matter?  What if there is progression in the lungs but response in lymphadenopathy, for example?  
1 Answer available
How do you manage hematologic toxicities in solid tumor patients treated with immune checkpoint inhibitors?
If these are presumed to be immune-mediated (e.g. immune neutropenia or immune thrombocytopenia), do you treat with steroids?
1 Answer available
Do you recommend using altered fractionation for a patient with squamous cell carcinoma of the skin in the head and neck region who cannot receive concurrent chemotherapy?
For example, if you had an octogenarian with a previously resected squamous cell carcinoma of the skin who presented with metastases to the parotid an...
1 Answer available
How do you manage an acute herpes zoster infection (shingles) in a radiation therapy treatment field where the skin is getting a significant dose of RT?
Do you give a treatment break? Is so, how long should RT be held? Are there skin management techniques to use?
1 Answer available
For a localized hidradenocarcinoma of the extremity managed with resection, what adjuvant dose to the surgical bed would you recommend?
Would this recommendation change based on proximity to a joint?
1 Answer available
When does perineural invasion for a squamous cell carcinoma of the skin of the head and neck merit adjuvant radiotherapy?
Following Mohs surgery and in the absence of other high risk features, do you offer RT for any PNI?  A single nerve < 0.1 mm? A single ne...
3 Answers available
How would you treat an unresectable SCC of the skin local recurrence in the base of skull with clinical and radiographic CN involvement?
Would you be comfortable with 55Gy in 20 fractions around the optic nerves and brainstem, or would you treat with a more protracted fractionation? Do ...
3 Answers available
What is the best management for recurrent basal cell carcinoma after prior radiation and vismodegib?
Would re-irradiation be an appropriate option? What dose/field would you incorporate? If treating with standard fractionation, would you take the enti...
1 Answer available
How do you manage an open wound that is not healing after radiation treatment for an ulcerated SCC of the scalp?
If the patient is a poor surgical candidate and is a symptomatic, can he or she live with this?
1 Answer available
How do you address the risks of radiation-induced carcinogenesis when counseling younger adult patients (40-60 years old) on definitive radiation therapy for non-melanomatous skin cancer of the head/neck?
Is there an age where the patient would be considered "too young" to receive definitive radiation therapy as opposed to surgery?
1 Answer available
When treating patients with immune checkpoint inhibitors, do you routinely check markers of endocrinopathies (i.e. TSH and ACTH) or only when a patient has symptoms?
If so, how often do you check these labs?
1 Answer available
For a patient treated with Mohs surgery for a high risk skin cancer of the head/neck, do you post-operatively treat all scars (including those created due to subsequent closure) to full dose?
I have seen some patients who may undergo large complex closures (sometimes as a separate procedure) for smaller lesions with resulting scars that sig...
3 Answers available
How should RT be combined with immunotherapy to generate an abscopal response?
Is there any consensus regarding the optimal RT dose, fractionation, and timing to the best abscopal response? What is the optimal metastatic site to ...
1 Answer available
What should be the first line treatment for metastatic uveal melanoma?
1 Answer available
What is your approach to patients with stage III melanoma now that the FDA has approved adjuvant ipilimumab for high risk stage III melanoma patients?
1 Answer available
Do you treat fully resected squamous cell carcinoma of the ear with cartilage invasion with adjuvant radiation?
If so, what is your treatment volume?
1 Answer available
How do you manage dabrafenib fever?
Decrease the dose? Treatment break? Steroids?
1 Answer available
When treating a high risk cutaneous squamous cell carcinoma post-operatively to the tumor bed, do you include the entire pre-op tumor in your PTV or do you include only the scar with margin?
For example, if a 5 x 5 cm squamaous cell carcinoma with deep invasion has been resected via Mohs with negative margins, will your PTV include the ent...
1 Answer available
What dose and fractionation do you use when you want an abbreviated course for incompletely resected squamous cell carcinoma of the pre-auricular area?
For example, in a demented, poor performance status, elderly patient?
1 Answer available
What is the value of resection in high risk (but small or early stage) skin cancers at the medial canthus?
Is modern surgical/reconstruction treatment superior to radiation therapy? If contact brachytherapy or superficial (orthovoltage) therapy isnt possib...
1 Answer available
Do you treat the surrounding erythema for cutaneous squamous or basal cell carcinoma?
Is the surrounding erythema as part of the GTV so that the margin is placed around the erythema rather than around the gross lesion only?
1 Answer available
What dose do you typically use when retreating locally aggressive and recurrent SCCs of the scalp (with no regional or distant mets)?
Assume all other options have been exhausted or are not feasible (e.g. systemic treatments, medically inoperable, etc.). Is there a BED or EQD2 that y...
1 Answer available
What is the best radiation technique for treating Kaposi sarcoma involving the irregular surfaces of the toes and soles of the feet?
1 Answer available
When should patients with metastatic melanoma be referred for treatment at an academic center?
With novel therapies quickly evolving, it's becoming more difficult to discern the proper sequence of therapies and the point at which a clinical tria...
1 Answer available
What is your approach to treating inoperable mucosal melanoma of the head and neck region?
What is the preferred dose, fractionation, and role of concurrent chemo? 
1 Answer available
For cutaneous SCC of the cheek with microscopic PNI, which nodal levels, if any, do you prophylactically treat?
Do you prophylactically treat the entire parotid gland as well?
1 Answer available
How do you best palliate metastatic skin and subcutaneous melanoma lesions?
Do you hypofractionate or add any concurrent systemic therapy? What specific dose-fractionation regimens do you recommend?
1 Answer available
Is there any data to support radiation and targeted agents (Braf inhibitor or ipilimumab) combined for stage III melanoma?
Even though data from TROG 02.01 showed 52% decrease in LR, I've heard some argue that toxicity is increased and that "it damages the blood vessels an...
1 Answer available


Papers discussed in this category

Oral oncology, 2018-03
Combination of post-operative radiotherapy and cetuximab for high-risk cutaneous squamous cell cancer of the head and neck: A propensity score analysis.
J. Clin. Oncol., 2018 Mar 14
Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: The Randomized Phase III TROG 05.01 Trial.
International journal of radiation oncology, biology, physics, 2004-11-01
Permanent alopecia after cranial irradiation: dose-response relationship.
JAMA Dermatol,
Assessment and Treatment Outcomes of Persistent Radiation-Induced Alopecia in Patients With Cancer.
Blood, 2015-07-23
Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study.
Cancer, 1995 May 1
Reirradiation of recurrent skin cancer of the face. A successful salvage modality.
Eur. J. Cancer, 2016-02-01
Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
JAMA dermatology, 2016-09-01
Recurrence and Survival in Patients With Merkel Cell Carcinoma Undergoing Surgery Without Adjuvant Radiation Therapy to the Primary Site.
Ann Surg Oncol, 2003 May
Sentinel lymph node biopsy for patients with cutaneous desmoplastic melanoma.
American journal of surgery, 2001-12
The clinical behavior of desmoplastic melanoma.
World J Surg, 1992 Mar-Apr
Desmoplastic melanoma: patterns of recurrence.
Cancer, 2005-10-01
Wide excision without radiation for desmoplastic melanoma.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2014-01
Delineation of the neck node levels for head and neck tumors: a 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines.
Radiation oncology (London, England), 2015-09-21
Efficacy of elective nodal irradiation in skin squamous cell carcinoma of the face, ears, and scalp.
Immunotherapy, 2016-10
Autoimmune meningoencephalitis in a melanoma patient treated with ipilimumab.
Med Dosim, 2013 Summer
A case study of radiotherapy planning for Intensity Modulation Radiation Therapy for the whole scalp with matching electron treatment.
Radiother Oncol, 1989-02-01
Radiation therapy of skin carcinomas: results of a hypofractionated irradiation schedule in 675 cases followed more than 2 years.
J. Clin. Oncol., 2018-06-10
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.
N Engl J Med, 2015 May 31
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
Cancer, 2011-10-15
Sphincter-sparing local excision and hypofractionated radiation therapy for anorectal melanoma: a 20-year experience.
International journal of radiation oncology, biology, physics, 2016-06-01
Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG).
The New England journal of medicine, 2017-11-09
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
Radiother Oncol, 2002-07-01
External beam radiotherapy of choroidal metastases--final results of a prospective study of the German Cancer Society (ARO 95-08).
N. Engl. J. Med., 2017-11-09
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2017-10
Hypofractionated radiation therapy for basal and squamous cell skin cancer: A meta-analysis.
Head Neck, 2011-12-01
Cutaneous squamous cell carcinoma of the head and neck metastasizing to the parotid gland--a review of current recommendations.
Br. J. Dermatol.,
Radiotherapy for lentigo maligna: a literature review and recommendations for treatment.
International journal of radiation oncology, biology, physics, 2017-03-15
SBRT in five fractions.
Int. J. Radiat. Oncol. Biol. Phys.,
An Ultracentral Lung Tumor.
Lancet (London, England), 2017-10-21
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
The Lancet. Oncology, 2016-11
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
The New England journal of medicine, 2017-10-05
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
J. Clin. Oncol.,
High-risk Merkel cell carcinoma of the skin treated with synchronous carboplatin/etoposide and radiation: a Trans-Tasman Radiation Oncology Group Study--TROG 96:07.
International journal of radiation oncology, biology, physics, 2009-04-01
Radiation therapy field extent for adjuvant treatment of axillary metastases from malignant melanoma.
Lancet Oncol, 2018 May
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
The Lancet. Oncology, 2016-10
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.
N Engl J Med, 2018 Apr 15
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.
The New England journal of medicine, 2012-03-08
Immunologic correlates of the abscopal effect in a patient with melanoma.
Practical radiation oncology, 2017
Potential abscopal response to dual checkpoint blockade in RCC after reirradiation using dose-painting SBRT.
PLoS One, 2016
Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy.
Int. J. Radiat. Oncol. Biol. Phys.,
A randomized study comparing two high-dose per fraction radiation schedules in recurrent or metastatic malignant melanoma.
Int. J. Radiat. Oncol. Biol. Phys., 2016 Jul 15
A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma.
Lancet Oncol., 2017 Mar 04
Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.
Lancet Oncol., 2012 May 09
Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial.
J Surg Oncol, 2018 Dec 18
Indications for the surgical resection of stage IV disease.
Clinical cancer research : an official journal of the American Association for Cancer Research, 2018-01-15
Toward Precision Radiotherapy for Use with Immune Checkpoint Blockers.
Therapeutic advances in medical oncology, 2018
Radiotherapy and checkpoint inhibitors: a winning new combination?
International journal of radiation oncology, biology, physics, 2002-03-15
Adjuvant irradiation for axillary metastases from malignant melanoma.
Lancet Oncol., 2014-11-01
Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.
Ann. Oncol., 2011 Jul 12
Adjuvant prophylactic regional radiotherapy versus observation in stage I Merkel cell carcinoma: a multicentric prospective randomized study.
Journal for immunotherapy of cancer, 2019-06-06
Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma.
J. Clin. Oncol., 2019 Feb 27
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.
Ophthalmology, 2002-10
Late radiation failures after iodine 125 brachytherapy for uveal melanoma compared with charged-particle (proton or helium ion) therapy.
Archives of ophthalmology (Chicago, Ill. : 1960), 2002-12
Evidence-based estimates of outcome in patients irradiated for intraocular melanoma.
Am. J. Ophthalmol.,
The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24.
International journal of radiation oncology, biology, physics, 2001-03-15
Proton radiation therapy for medium and large choroidal melanoma: preservation of the eye and its functionality.
Int. J. Radiat. Oncol. Biol. Phys., 2017 Feb 17
Stereotactic Radiosurgery and Fractionated Stereotactic Radiation Therapy for the Treatment of Uveal Melanoma.
Br J Ophthalmol, 2013 Jan 19
A comparison between ¹²⁵Iodine brachytherapy and stereotactic radiotherapy in the management of juxtapapillary choroidal melanoma.
JAMA Ophthalmol,
Retrospective evaluation of patients with uveal melanoma treated by stereotactic radiosurgery with and without tumor resection.
International journal of radiation oncology, biology, physics, 2013-05-01
Charged particle radiation therapy for uveal melanoma: a systematic review and meta-analysis.
International journal of radiation oncology, biology, physics, 2017-01-01
Temporal Evolution and Dose-Volume Histogram Predictors of Visual Acuity After Proton Beam Radiation Therapy of Uveal Melanoma.
International journal of radiation oncology, biology, physics, 2015-06-01
Long-term Results of the UCSF-LBNL Randomized Trial: Charged Particle With Helium Ion Versus Iodine-125 Plaque Therapy for Choroidal and Ciliary Body Melanoma.
Int. J. Radiat. Oncol. Biol. Phys.,
Maximizing local tumor control and survival after proton beam radiotherapy of uveal melanoma.
Investigative ophthalmology & visual science, 2006-11
Proton beam irradiation of uveal melanomas: the first 30 years. The Weisenfeld Lecture.
PloS one, 2015
Cost-effectiveness of proton beam therapy for intraocular melanoma.
Br J Ophthalmol, 2013 May 03
Local treatment failure after globe-conserving therapy for choroidal melanoma.
Int J Radiat Oncol Biol Phys, 2016 Jan 28
Practice Patterns Analysis of Ocular Proton Therapy Centers: The International OPTIC Survey.
Saudi J Ophthalmol,
Proton beam radiotherapy of uveal melanoma.
Journal of contemporary brachytherapy, 2017-04
Electronic brachytherapy management of atypical fibroxanthoma: report of 8 lesions.
Melanoma research, 2015-04
The emerging role of radiotherapy for desmoplastic melanoma and implications for future research.
Nature, 2018-01-18
High response rate to PD-1 blockade in desmoplastic melanomas.
Cureus, 2019 Jun 18
Desmoplastic Melanoma: Clinical Characteristics and Survival in the US Population.
PloS one, 2015
Clinicopathologic predictors of survival in patients with desmoplastic melanoma.
Semin. Cancer Biol., 2019 Jul 19
Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review.
J Natl Compr Canc Netw,
Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors.
Int. J. Radiat. Oncol. Biol. Phys.,
Radiation effect in mouse skin: dose fractionation and wound healing.
J. Clin. Oncol., 2019 Dec 27
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.
The British journal of dermatology, 2019-02
Local recurrence and quality of life after adjuvant radiation therapy in high-risk squamous cell carcinoma.
JAAD Case Rep, 2019 Jun 26
Radiation therapy for primary cutaneous γδ T-cell lymphoma: Case report and literature review.
Pract Radiat Oncol, 2019 Dec 09
Definitive and Postoperative Radiation Therapy for Basal and Squamous Cell Cancers of the Skin: Executive Summary of an American Society for Radiation Oncology Clinical Practice Guideline.
Radiother Oncol, 2010 Mar 23
Efficacy of a hypofractionated schedule in electron beam radiotherapy for epithelial skin cancer: Analysis of 434 cases.
Lancet (London, England), 2004-05-22
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial.
The Lancet. Oncology, 2016-07
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.
International journal of radiation oncology, biology, physics, 2018-03-15
Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
The New England journal of medicine, 2018-08-23
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-01-01
Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial.
J. Clin. Oncol., 2019 Sep 25
Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial.
Clin Oncol (R Coll Radiol),
Final results of the Royal College of Radiologists' trial comparing two different radiotherapy schedules in the treatment of cerebral metastases.
Lancet Oncol., 2018 Mar 27
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
Cochrane Database Syst Rev, 2012 Apr 18
Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases.
Cancer, 2016 Jun 10
Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.
International journal of radiation oncology, biology, physics, 2017-11-15
Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA).
International journal of radiation oncology, biology, physics, 1997-03-01
Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials.
Neurosurgery, 2020 Apr 21
Changing Therapeutic Landscape for Melanoma With Multiple Brain Metastases.
J. Am. Acad. Dermatol.,
Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 patients.
J. Am. Acad. Dermatol., 2011 Oct 24
Grenz ray treatment of lentigo maligna and early lentigo maligna melanoma.
J Am Acad Dermatol, 2019 Sep 25
Restaging [F] fludeoxyglucose positron emission tomography/computed tomography scan in recurrent cutaneous squamous cell carcinoma: Diagnostic performance and prognostic significance.
JAMA ophthalmology, 2016-08-01
Subretinal Fluid Associated With MEK Inhibitor Use in the Treatment of Systemic Cancer.
Lancet Oncol, 2015 Jul 20
Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial.
N Engl J Med, 2019 Sep 28
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
Lancet Oncol, 2019 Dec
Sebaceous carcinoma: evidence-based clinical practice guidelines.
Melanoma research, 2017-06
Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma.
JAMA Dermatol,
Prevalence and Gross Morphologic Features of Perianal Melanocytic Nevi.
Pathology, 2018 Nov 26
Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 cases.
Semin Cancer Biol, 2019 Oct 23
The mutational landscape of mucosal melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002-12-01
Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma.
Journal of medical case reports, 2010-05-22
Treatment of eccrine porocarcinoma with metastasis to the parotid gland using intensity-modulated radiation therapy: a case report.
Ann Med Surg (Lond), 2017 Jun 20
Porocarcinoma; presentation and management, a meta-analysis of 453 cases.
Case Rep Oncol, 2021 May 10
Eccrine Porocarcinoma: A Challenging Diagnostic and Therapeutic Tumoral Entity.
J Clin Oncol,
Analyzing the same data in two ways: a demonstration model to illustrate the reporting and misreporting of clinical trials.
Int J Radiat Oncol Biol Phys,
Dosimetric evaluation of lead and tungsten eye shields in electron beam treatment.
Journal of the American College of Surgeons, 2011-04
Shave biopsy is a safe and accurate method for the initial evaluation of melanoma.
Am J Surg,
Effect of biopsy type on outcomes in the treatment of primary cutaneous melanoma.
Ann Pharmacother, 2021 Jul 20
Impact of Proton Pump Inhibitor Use on the Effectiveness of Immune Checkpoint Inhibitors in Advanced Cancer Patients.
Ann Transl Med,
The effect of proton pump inhibitor uses on outcomes for cancer patients treated with immune checkpoint inhibitors: a meta-analysis.
Can Fam Physician,
Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline.
Dermatol Clin,
Skin Cancer Risk (Nonmelanoma Skin Cancers/Melanoma) in Vitiligo Patients.
J Am Acad Dermatol, 2014 Sep 19
Markedly reduced incidence of melanoma and nonmelanoma skin cancer in a nonconcurrent cohort of 10,040 patients with vitiligo.
Br J Dermatol,
Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: a survey among 1307 patients and their partners.
East Afr Med J,
PRIMARY MALIGNANT AMELANOTIC MELANOMA ARISING FROM A VITILIGO PATCH OF AN AFRICAN TANZANIAN: CASE REPORT.
Int J Dermatol,
Molecular analysis of vitiligo lesions reveals sporadic melanocyte survival.
J Pathol,
Melanocytes are not absent in lesional skin of long duration vitiligo.
Sci Rep, 2021 Oct 12
Reduced risk of skin cancer and internal malignancies in vitiligo patients: a retrospective population-based cohort study in Taiwan.
Acta Derm Venereol,
Prediction of the Occurrence of Melanoma and Non-melanoma Skin Cancer in Patients with Vitiligo.
Br J Dermatol, 2019 Sep 18
The incidence and survival of melanoma and nonmelanoma skin cancer in patients with vitiligo: a nationwide population-based matched cohort study in Korea.
Br J Dermatol, 2019 Oct 16
Vitiligo and skin cancer: is it a question of ethnicity?
N Engl J Med,
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
The American Journal of dermatopathology, 2013-07
SOX10 expression distinguishes desmoplastic melanoma from its histologic mimics.
The American journal of surgical pathology, 2018-03
Distinguishing Neurofibroma From Desmoplastic Melanoma: The Value of p53.
The American journal of surgical pathology, 2018-11
PRAME Expression in Melanocytic Tumors.
Appl Immunohistochem Mol Morphol,
SOX10 expression in malignant melanoma, carcinoma, and normal tissues.
Pathology, 2016 Aug 28
SOX10 expression in cutaneous scars: a potential diagnostic pitfall in the evaluation of melanoma re-excision specimens.
Am J Dermatopathol,
Sox10-Positive Cells Within Scars: A Potential Diagnostic Pitfall.
Am J Dermatopathol,
SOX-10 and S100 Negative Desmoplastic Melanoma: Apropos a Diagnostically Challenging Case.
J Am Acad Dermatol, 2022 Jun 23
Value of Permanent Pathology for Debulk and Mohs Specimens during Mohs Micrographic Surgery for Cutaneous Squamous Cell Carcinoma: A Retrospective Cohort Study.
Dermatol Surg,
Utility of Debulk Specimens During Mohs Micrographic Surgery for Cutaneous Squamous Cell Carcinoma.

Related Topics

Copyright © 2025 theMednet
All Rights Reserved.